Our verdict is Benign. Variant got -19 ACMG points: 1P and 20B. PP2BP4_StrongBP6_Very_StrongBS1BS2
The NM_001148.6(ANK2):c.11791G>A(p.Glu3931Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00343 in 1,614,190 control chromosomes in the GnomAD database, including 21 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
ANK2 (HGNC:493): (ankyrin 2) This gene encodes a member of the ankyrin family of proteins that link the integral membrane proteins to the underlying spectrin-actin cytoskeleton. Ankyrins play key roles in activities such as cell motility, activation, proliferation, contact and the maintenance of specialized membrane domains. Most ankyrins are typically composed of three structural domains: an amino-terminal domain containing multiple ankyrin repeats; a central region with a highly conserved spectrin binding domain; and a carboxy-terminal regulatory domain which is the least conserved and subject to variation. The protein encoded by this gene is required for targeting and stability of Na/Ca exchanger 1 in cardiomyocytes. Mutations in this gene cause long QT syndrome 4 and cardiac arrhythmia syndrome. Multiple transcript variants encoding different isoforms have been described. [provided by RefSeq, Dec 2011]
PP2 - Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease
Missense variant where missense usually causes diseases, ANK2
BP4
?
BP4 - Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.)
Computational evidence support a benign effect (MetaRNN=0.027564794).
BP6
?
BP6 - Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation
Variant 4-113373381-G-A is Benign according to our data. Variant chr4-113373381-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 18060.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr4-113373381-G-A is described in Lovd as [Likely_benign]. Variant chr4-113373381-G-A is described in Lovd as [Benign].
BS1
?
BS1 - Allele frequency is greater than expected for disorder
Variant frequency is greater than expected in population mid. gnomad4_exome allele frequency = 0.00355 (5187/1461870) while in subpopulation MID AF= 0.00537 (31/5768). AF 95% confidence interval is 0.00389. There are 21 homozygotes in gnomad4_exome. There are 2546 alleles in male gnomad4_exome subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
?
BS2 - Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age
Likely benign, criteria provided, single submitter
clinical testing
Illumina Laboratory Services, Illumina
Apr 27, 2017
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. -
Likely benign, criteria provided, single submitter
clinical testing
Mendelics
May 28, 2019
- -
Uncertain significance, no assertion criteria provided
literature only
OMIM
Jun 15, 2004
- -
Benign, criteria provided, single submitter
clinical testing
Genome-Nilou Lab
Dec 05, 2021
- -
not provided Benign:3
Benign, criteria provided, single submitter
clinical testing
CeGaT Center for Human Genetics Tuebingen
Jan 01, 2024
ANK2: BP4, BS1, BS2 -
Likely benign, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Mar 07, 2016
Variant summary: Variant affects a conserved nucleotide and results in a replacement of a medium size acidic Glutamate (E) with a large size and basic Lysine (K). 2/5 in silico tool predict deleterious outcome for this change. It was found in the large and broad cohorts of NHLBI-ESP; ExAC and 1000G projects as well as in healthy control individuals in disease specific publications at a composite allele frequency of 0.26.8% which greatly exceeds the maximal allele frequency of a disease causing ANK2 allele (0.001%) indicating a benign impact. In addition, there are three homozygous individuals reported in ExAC further supporting a non-disease causing outcome. Variant was found in ARTHY patients however because of the lack of familial segregation data or comprehensive ANK2 testing these studies do not permit establishment of a cause-effect relationship between the variant and ARTHY (Mohler_PNAS_2004; Mohler_Circ_2007). One research group investigated the impact of the variant on the function of the protein and concluded that overall, the variant has negligible loss of function impact on the protein (Mohler_Circulation_2007). Clinical diagnostic centers classify variant as Benign/Likely Benign via ClinVar without evidence to independently evaluate. Taken together, evidences support a benign nature for the variant, therefore variant was classified as likely benign. -
Likely benign, criteria provided, single submitter
clinical testing
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Jan 25, 2017
- -
not specified Benign:2
Benign, criteria provided, single submitter
clinical testing
GeneDx
Jul 25, 2017
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Likely benign, criteria provided, single submitter
clinical testing
Eurofins Ntd Llc (ga)
Dec 04, 2014
- -
Cardiac arrhythmia Benign:1Other:1
Benign, criteria provided, single submitter
research
Biesecker Lab/Clinical Genomics Section, National Institutes of Health
Jun 24, 2013
- -
not provided, no classification provided
literature only
Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust
-
This variant has been reported as associated with Cardiac arrhythmia in the following publications (PMID:15178757). This is a literature report, and does not necessarily reflect the clinical interpretation of the Imperial College / Royal Brompton Cardiovascular Genetics laboratory. -
ANK2-related disorder Benign:1
Benign, criteria provided, single submitter
clinical testing
PreventionGenetics, part of Exact Sciences
May 07, 2019
This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Ventricular fibrillation Benign:1
Benign, criteria provided, single submitter
clinical testing
Center for Advanced Laboratory Medicine, UC San Diego Health, University of California San Diego
Oct 02, 2018
- -
Long QT syndrome Benign:1
Benign, criteria provided, single submitter
clinical testing
Invitae
Jan 31, 2024
- -
Cardiovascular phenotype Benign:1
Benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Jun 13, 2016
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -